Skip to main content

Table 3 LMS-QoL values for completers vs. non-completers and percentages of patients with improved, unchanged and worsened HR-QoL at month 12.

From: Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational, international, multi-centre study

LMS-QoL

Parameters

Total group completers

Total group non-completers

Treatment-naive completers

Treatment-naive non-completers

Baseline (B)

Mean (SD)

19.84 (4.15)

18.66 (4.20)

19.59 (4.23)

19.35 (4.49)

 

Median

20.00

19.00

19.00

20.00

 

95% CI (mean)

19.15; 20.54

17.54; 19.79

18.67; 20.51

17.41; 21.29

Change B to M12

Mean (SD)

1.76 (4.25)*

-0.21 (3.91)

2.52 (4.72)*

-0.06 (2.91)

 

Median

1.00

0.00

2.00

0.00

 

95% CI (mean)

1.05; 2.47

-1.47; 1.06

1.49; 3.56

-1.61; 1.49

Improved M12

n (%)

59 (42.1)

5 (12.8)

40 (48.8)

2 (12.5)

Unchanged

n (%)

65 (46.4)

25 (64.1)

34 (41.5)

10 (62.5)

Worsened

n (%)

16 (11.4)

9 (23.1)

8 (9.8)

4 (25.0)

  1. *, p < 0.001.